The impact of hysterectomy on oncological outcomes in postmenopausal patients with borderline ovarian tumors: A multicenter retrospective study.
cancer
carcinoma
death
recurrence
salpingo-oophorectomy
tumours
uterus
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
08
2022
accepted:
12
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Data about the oncological outcomes in women with borderline ovarian tumor (BOT) undergoing uterine-sparing surgery without ovarian preservation are poor. We aimed to assess the oncological outcomes in women with BOT undergoing uterine-sparing surgery without ovarian preservation. A multi-center observational retrospective cohort study was performed including all consecutive postmenopausal patients who underwent surgical treatment for BOT at three tertiary level referral centers for gynecologic oncology from January 2005 to December 2016. Patients were divided into two groups for comparisons: patients undergoing hysterectomy (hysterectomy group) and patients undergoing uterine-sparing surgery (no hysterectomy group). Study outcomes were disease-free survival (DFS), overall survival (OS), disease-specific survival (DSS) and surgical complications rate. Ninety-eight patients were included: 44 in the hysterectomy group and 54 in the no hysterectomy group. The 5- and 10-year DFS rates were 97.7% (95% CI: 84.9-99.7) and 92.3% (95% CI: 69.7-98.2), in the hysterectomy group, and 86.8% (95% CI: 74.3-93.5) and 86.8% (95% CI: 74.3-93.5), in the no hysterectomy group, respectively, without significant differences (p=0.16). Hazard ratio for DFS was 0.26 (95% CI: 0.06-1.68) for the hysterectomy group. The 5- and 10-year OS rates were 100.0% (95% CI: -) and 100.0% (95% CI: -), in the hysterectomy group, and 98.2% (95% CI: 87.6-99.7) and 94.4% (95% CI: 77.7-98.7), in the no hysterectomy group, respectively, without significant differences (p=0.23). No significant difference in complication rate was reported among the groups (p=0.48). As hysterectomy appears to not impact survival outcomes of women with BOT, it might be avoided in the surgical staging.
Identifiants
pubmed: 36387131
doi: 10.3389/fonc.2022.1009341
pmc: PMC9647053
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1009341Informations de copyright
Copyright © 2022 Raimondo, Raffone, Scambia, Maletta, Lenzi, Restaino, Mascilini, Trozzi, Mauro, Travaglino, Driul, Casadio, Mollo, Fagotti, Vizzielli and Seracchioli.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arch Gynecol Obstet. 2015 Jan;291(1):123-30
pubmed: 25047273
Int J Gynecol Cancer. 2011 May;21(4):640-6
pubmed: 21543929
Int J Gynecol Cancer. 2007 Mar-Apr;17(2):342-9
pubmed: 17343573
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8
pubmed: 25341581
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Surg Oncol. 2016 Mar;25(1):1-5
pubmed: 26979634
J Chin Med Assoc. 2011 Jun;74(6):250-4
pubmed: 21621167
Oncotarget. 2017 Dec 06;8(70):115718-115729
pubmed: 29383195
J Clin Oncol. 2001 May 15;19(10):2658-64
pubmed: 11352957
Obstet Gynecol. 2013 Mar;121(3):654-673
pubmed: 23635631
Oncologist. 2012;17(12):1515-33
pubmed: 23024155
Int J Gynecol Cancer. 2019 May 2;:
pubmed: 31048403
Gynecol Obstet Fertil Senol. 2020 Mar;48(3):287-303
pubmed: 32004786
Gynecol Oncol. 2005 Jun;97(3):845-51
pubmed: 15896834
Gynecol Oncol Rep. 2021 Feb 12;36:100730
pubmed: 33665295
Gynecol Oncol. 2012 May;125(2):372-5
pubmed: 22366596
Ann Surg Oncol. 2006 Apr;13(4):565-71
pubmed: 16491337
Case Rep Oncol. 2019 Sep 25;12(3):728-736
pubmed: 31616281
Am J Obstet Gynecol. 2014 Dec;211(6):637.e1-6
pubmed: 24949545
Br J Cancer. 2006 Jun 5;94(11):1586-91
pubmed: 16685277
Fertil Steril. 2003 May;79(5):1216-21
pubmed: 12738521
J Gynecol Obstet Hum Reprod. 2021 Apr;50(4):101961
pubmed: 33127559
Eur J Cancer. 2013 May;49(8):1905-14
pubmed: 23490647
Fertil Steril. 2001 Nov;76(5):999-1004
pubmed: 11704124
Gynecol Oncol. 2008 Aug;110(2):162-7
pubmed: 18495223
Virchows Arch. 2017 Feb;470(2):125-142
pubmed: 28025670
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898
pubmed: 32634781
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Gynecol Oncol. 2022 Apr;165(1):184-191
pubmed: 35090745